Patents by Inventor Kevin Tracey

Kevin Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190201499
    Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.
    Type: Application
    Filed: September 8, 2017
    Publication date: July 4, 2019
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: William Hanes, Kevin Tracey, Peder Olofsson
  • Patent number: 9005615
    Abstract: The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: April 14, 2015
    Assignee: The Feinstein Institute For Medical Research
    Inventors: Kevin Tracey, Sangeeta Chavan
  • Patent number: 8715658
    Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 6, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin Tracey, William Parrish
  • Publication number: 20130071389
    Abstract: The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.
    Type: Application
    Filed: May 5, 2011
    Publication date: March 21, 2013
    Applicant: The Feinstein Institute For Medical Research
    Inventors: Kevin Tracey, Sangeeta Chavan
  • Publication number: 20120219546
    Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.
    Type: Application
    Filed: August 17, 2010
    Publication date: August 30, 2012
    Applicant: The Feinstein Institute for Medical Research
    Inventors: Kevin Tracey, William Parrish
  • Publication number: 20110236406
    Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.
    Type: Application
    Filed: January 18, 2011
    Publication date: September 29, 2011
    Applicants: MedImmune, LLC, The Feinstein Institute for Medical Research
    Inventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
  • Publication number: 20090297499
    Abstract: The invention relates to the use of charcoal in the manufacture of an oral composition for the treatment of an inflammatory condition other than an inflammatory bowel disease and other than interstitial or other inflammation within the kidney.
    Type: Application
    Filed: August 4, 2006
    Publication date: December 3, 2009
    Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Brian M. Foxwell, Percy Sumariwalla, Paul Kaye, Kevin Tracey, Kenneth Kenigsberg, Luis Ulloa
  • Publication number: 20080305120
    Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.
    Type: Application
    Filed: June 16, 2005
    Publication date: December 11, 2008
    Applicants: MEDIMMUNE, INC., THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
  • Publication number: 20080070901
    Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
    Type: Application
    Filed: August 14, 2007
    Publication date: March 20, 2008
    Inventors: Kevin Tracey, Valentin Pavlov
  • Publication number: 20080004207
    Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.
    Type: Application
    Filed: February 6, 2007
    Publication date: January 3, 2008
    Applicants: University of pittsburgh of the Commonwealth System of Higher Education, The Feinstein Institute for Medical Research
    Inventors: Allan Tsung, Timothy Billiar, Mitchell Fink, Kevin Tracey
  • Publication number: 20070238640
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Application
    Filed: April 13, 2007
    Publication date: October 11, 2007
    Inventors: Kevin Tracey, Huan Yang
  • Publication number: 20070213350
    Abstract: A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacological agent that increases the activity of cholinergic receptor in a subject. Examples of pharmacological agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can be used to treat ileus caused by abdominal surgery, or administration of narcotics or chemotherapeutic agents such as during cancer chemotherapy.
    Type: Application
    Filed: December 22, 2006
    Publication date: September 13, 2007
    Inventors: Kevin Tracey, Mitchell Fink
  • Publication number: 20070021465
    Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (Ia) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (Ia) or (VIIa). The variables of Formulae (I), (Ia), (VII) and (VIIa) are described herein.
    Type: Application
    Filed: October 7, 2004
    Publication date: January 25, 2007
    Inventors: Yousef Al-Abed, Kevin Tracey
  • Publication number: 20060258579
    Abstract: Methods of inhibiting HMGB1 release by a mammalian cell are provided. The methods comprise treating the cell with sufficient fetuin to inhibit HMGB1 release. Methods of inhibiting an inflammatory cytokine cascade in a mammal are also provided. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal. Also provided are methods of treating a condition in a mammal characterized by an inflammatory cytokine cascade. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal.
    Type: Application
    Filed: May 13, 2005
    Publication date: November 16, 2006
    Inventors: Kevin Tracey, Haichao Wang, Andrew Sama
  • Publication number: 20060240019
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a phamaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: June 29, 2006
    Publication date: October 26, 2006
    Inventors: Kevin Tracey, Haichao Wang
  • Publication number: 20060210565
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 21, 2006
    Inventors: Kevin Tracey, Haichao Wang
  • Publication number: 20060178703
    Abstract: A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: December 22, 2005
    Publication date: August 10, 2006
    Inventors: Jared Huston, Kevin Tracey
  • Publication number: 20060121047
    Abstract: The present invention features polypeptides comprising an HMGB B box or a functional variant thereof that are useful for stimulating or increasing an immune response in an individual. Such polypeptides can be used in vaccine formulations and in cancer therapies.
    Type: Application
    Filed: November 19, 2003
    Publication date: June 8, 2006
    Inventor: Kevin Tracey
  • Publication number: 20050282906
    Abstract: Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist or acetylcholinesterase inhibitor to the subject.
    Type: Application
    Filed: March 24, 2005
    Publication date: December 22, 2005
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin Tracey, Carol Amella, Christopher Czura
  • Publication number: 20050245609
    Abstract: This invention is directed to a method of using a therapeutic composition comprising an ester of an alpha-ketoalkanoic acid for the treatment of cytokine-mediated inflammatory conditions. The cytokine-mediated inflammatory conditions are mediated by, for example, Tumor Necrosis Factor (TNF), interleukin-1? (IL-1?)) or High Mobility Group B-1 (HMGB-1) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.
    Type: Application
    Filed: March 31, 2005
    Publication date: November 3, 2005
    Applicants: University of Pittsburgh of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell Fink, Luis Ulloa, Kevin Tracey, Russell Delude